Human-like mouse models for testing the efficacy and safety of anti-β 2-microglobulin monoclonal antibodies to treat myeloma

Clinical Cancer Research

Volumn 15, Issue 3, 2009, Pages 951-959

  Yang, Jing ^a   Cao, Yabing ^a   Hong, Sungyongl ^a   Li, Haiyan ^a   Qian, Jianfei ^a   Kwak, Larry W ^a   Yi, Qing ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY BETA 2 MICROGLOBULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; MOUSE; MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; HLA-A2 ANTIGEN; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; MULTIPLE MYELOMA;

EID: 61549121739     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1823     Document Type: Article

References (41)

1. Anderson KC. Advances in the biology of multiple myeloma: therapeutic applications. Semin Oncol 1999;26:10-22.
2. Anderson KC. Multiple myeloma: how far have we come? Mayo Clin Proc 2003;78:15-7.
3. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93:55-65.
4. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood 2004;103:20-32.
5. Anderson KC. Targeted therapy for multiple myeloma. Semin Hematol 2001;38:286-94.
6. Anderson KC. New agents and approaches in the treatment of multiple myeloma. Clin Adv Hematol Oncol 2003;1:151 -2.
7. Anderson KC,AndersenJ,SoifferR,etal. Monoclonal antibody-purgedb one marrow transplantation therapy for multiple myeloma. Blood 1993;82:2568-76.
8. Anderson KC, Kyle RA, Dalton WS, et al. Multiple 'myeloma: new insights and therapeutic approaches. Hematology (Am Soc Hematol Educ Program) 2000;:147-65.
9. Anderson DR, Grillo-Lopez A,Varns C, et al. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem SocTrans 1997;25:705-8.
10. Bauwens D, Maerevoet M, Michaux L, et al. Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma. Br J Haematol 2005;131:338-40.
11. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002;29: 2-9.
12. nrust SV, Lamb HM, BalfourJA Rituximab Drugs 1999;58:79-88; discussion 89-90.
13. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003;63:803-43.
14. Saleh M. Monoclonal antibody therapy of non- Hodgkin's lymphoma: the rituximab story. J Med Assoc Ga 2003;92:39-46.
15. Hofer S, Hunziker S, Dirnhofer S, et al. Rituximab effective in a patient with refractory autoimmune haemolytic anaemia and CD20-negative multiple myeloma. Br J Haematol 2003;122:690-1.
16. Treon SP, Pilarski LM, Belch AR, et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 2002;25:72-81.
17. Zojer N, Kirchbacher K, Vesely M, et al. Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma. Leuk Lymphoma 2006;47:1103-9.
18. Qi CJ, Zheng L, Zhou X, et al. Cross-linking f CD40 using anti-CD40 antibody, 5C11, has different effects on XG2multiple myeloma cells. Immunol Lett 2004;93:151 - 8.
19. Tai YT, Catley LP, Mitsiades CS, et al. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res 2004;64: 2846-52.
20. Tai YT, Li X,Tong X, et al. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res 2005; 65:5898-906.
21. Sekimoto E, Ozaki S, OhshimaT, et al. A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment. Cancer Res 2007;67: 1184-92.
22. Goy A New directions in the treatment of mantle cell lymphoma: an overview Clin Lymphoma Myeloma 2006;7 Suppl 1:S24-32
23. Descamps G, Wuilleme-Toumi S, Trichet V, et al CD45neg but not CD45pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a
24. Trudel S, Stewart AK,Rom E,et al The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells Blood 2006;107: 4039 -46
25. Walker KZ, Boux HA, Hayden GE, et al Amonoclo- nal antibody with selectivity for human κ myeloma and lymphoma cells which has potential as a therapeutic agent Adv Exp Med Biol 1985;186:833 -41
26. Bataille R, Barlogie B, Lu ZY, et al Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma Blood 1995; 86:685-91
27. Huang YW, Vitetta ES A monoclonal anti-human IL-6 receptor antibody inhibits the proliferation of human myeloma cells Hybridoma 1993;12:621 -30
28. Yang J, Qian J, Wezeman M, et al. Targeting β(2)- microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell 2006;10:295-307.
29. Yang J, Zhang X, Wang J, et al. Anti β2-microglobu- lin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood 2007;110:3028-35.
30. Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biologyand treatment of myeloma and itsmanifes- tations. Blood 1998;92:2908-13.
31. Skov S, Bregenholt S, Claesson MH. MHC class I ligation of human T ells activates the ZAP70 and p56lck tyrosine kinases, leads to an alternative phenotype of the TCR/CD3 ζ-chain, and induces apoptosis. J Immunol 1997;158:3189-96.
32. Pedersen AE, Bregenholt S, Skov S, et al. Protein tyrosine kinases p53/56lyn and p72syk in MHC class I-mediated signal transduction in B lymphoma cells. Exp Cell Res 1998;240:144-50.
33. Yaccoby S, Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 1999;94:3576-82.
34. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;33: 369-85.
35. Fan Z, Baselga J, Masui H, et al. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993; 53:4637-42.
36. Mendelsohn J. Epidermal growth factor receptor in hibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 1997;3:2703-7.
37. Le AX, Bernhard EJ, Holterman MJ, et al. Cytotoxic T cell responses in HLA-A2.1 transgenic mice. Recognition of HLA alloantigens and utilization of HLA-A2.1 as a restriction element. J Immunol 1989; 142:1366-71.
38. Skov S, Odum N, Claesson MH. MHC class I signaling in T cells leads to tyrosine kinase activity and PLC-γ1 phosphorylation. J Immunol 1995;154: 1167-76.
39. Vacca A, Ria R, Ribatti D, et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 2003;88: 176-85.
40. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19: 6550-65.
41. Kovacs MJ, Reece DE, Marcellus D, et al. A phase II study of ZD6474 (Zactima), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma-NCIC CTG IND.145. Invest New Drugs 2006;24:529-35.